Literature DB >> 3548807

The enigma of herpes stromal disease.

J McGill.   

Abstract

Herpes stromal disease is due to direct damage as a result of viral replication, virally induced immune mechanisms, or a combination of the two. Viral replication may have a major initiating role in the production of herpes simplex and herpes zoster induced stromal disease, and steroids may initially be harmful in their treatment. On topical antiviral drugs alone, in patients who never previously had had topical steroids, 14 of 15 cases of herpes simplex induced disciform keratitis responded favourably in an average of 44 days of treatment. This compared with one out of 14 responding if steroids had previously been used, 13 of 14 requiring topical steroids and an average 112 days' treatment. In herpes zoster stromal disease cases 78% had epithelial involvement, 54 of 57 responded to topical antivirals alone without the use of steroids, 2% recurred, and treatment averaged a total of 62 days. If steroids were used alone or in combination with antivirals, there was a 50% recurrence rate and 200 day total treatment duration.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3548807      PMCID: PMC1041102          DOI: 10.1136/bjo.71.2.118

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  43 in total

1.  TREATMENT OF HERPES ZOSTER WITH HIGH DOSES OF PREDNISONE.

Authors:  F A ELLIOTT
Journal:  Lancet       Date:  1964-09-19       Impact factor: 79.321

2.  Deep forms of herpetic keratitis.

Authors:  P THYGESON; S J KIMURA
Journal:  Am J Ophthalmol       Date:  1957-04       Impact factor: 5.258

Review 3.  Objectives in therapy of herpetic eye disease.

Authors:  B R Jones; M G Falcon; H P Williams; D J Coster
Journal:  Trans Ophthalmol Soc U K       Date:  1977-07

4.  Herpes zoster keratitis.

Authors:  R J Marsh
Journal:  Trans Ophthalmol Soc U K       Date:  1973

5.  Electron microscope observation of herpes-like particles in the iris.

Authors:  R Witmer; T Iwamoto
Journal:  Arch Ophthalmol       Date:  1968-03

6.  Acyclovir in herpes zoster.

Authors:  N A Peterslund; K Seyer-Hansen; J Ipsen; V Esmann; H Schonheyder; H Juhl
Journal:  Lancet       Date:  1981-10-17       Impact factor: 79.321

7.  Varicella-zoster virus in the human corneal endothelium: a case report.

Authors:  P C Maudgal; L Missotten; E De Clercq; J Descamps
Journal:  Bull Soc Belge Ophtalmol       Date:  1980

8.  Spread of virus and distribution of latent infection following ocular herpes simplex in the non-immune and immune mouse.

Authors:  A B Tullo; C Shimeld; W A Blyth; T J Hill; D L Easty
Journal:  J Gen Virol       Date:  1982-11       Impact factor: 3.891

9.  Necrotizing retinopathy with herpes zoster ophthalmicus: a light and electron microscopical study.

Authors:  J N Schwartz; F Cashwell; H K Hawkins; G K Klintworth
Journal:  Arch Pathol Lab Med       Date:  1976-07       Impact factor: 5.534

10.  Herpetic iridocyclitis.

Authors:  K R Wilhelmus; M G Falcon; B R Jones
Journal:  Int Ophthalmol       Date:  1982-02       Impact factor: 2.031

View more
  5 in total

1.  Spontaneous reduction in myopic correction following varicella disciform stromal keratitis.

Authors:  Y F Choong; N R Hawksworth
Journal:  Br J Ophthalmol       Date:  2002-08       Impact factor: 4.638

2.  The current management of herpetic eye disease.

Authors:  L M Collum; W J Power; A Collum
Journal:  Doc Ophthalmol       Date:  1992       Impact factor: 2.379

3.  Acyclovir ointment plus topical betamethasone or placebo in first episode disciform keratitis.

Authors:  W J Power; M P Hillery; A Benedict-Smith; L M Collum
Journal:  Br J Ophthalmol       Date:  1992-12       Impact factor: 4.638

4.  Herpes simplex virus type 1 penetrates the basement membrane in human nasal respiratory mucosa.

Authors:  Sarah Glorieux; Claus Bachert; Herman W Favoreel; Annelies P Vandekerckhove; Lennert Steukers; Anamaria Rekecki; Wim Van den Broeck; Joline Goossens; Siska Croubels; Reginald F Clayton; Hans J Nauwynck
Journal:  PLoS One       Date:  2011-07-15       Impact factor: 3.240

5.  Clinical efficacy of oral and topical acyclovir in herpes simplex virus stromal necrotizing keratitis.

Authors:  Surabhi Dutt; Manisha Acharya; Abha Gour; Neelam Sapra; Lokesh Chauhan; Umang Mathur
Journal:  Indian J Ophthalmol       Date:  2016-04       Impact factor: 1.848

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.